SEC Form 4 · accession 0000899243-18-020661
Cardiff Oncology, Inc. · CRDF
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mark Erlander
Officer — Chief Scientific Officer
Period of report
Jul 24, 2018
Accepted (ET)
Jul 26, 2018 · 4:30 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001213037
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF1,F2 | — | Jul 24, 2018 | A | 45,000 | A | — | — | Common Stock | 45,000 | 49,688 | D |
Explanation of responses
- F1Each restricted stock unit is the economic equivalent of one share of Trovagene, Inc. common stock.
- F27,500 of the RSUs will vest on each of October 1, 2018, January 1, 2019, April 1, 2019, July 1, 2019, October 1, 2019 and January 1, 2020.